Article ID Journal Published Year Pages File Type
5699077 Clinical Oncology 2012 5 Pages PDF
Abstract
Recombinant human thyroid-stimulating hormone-stimulated 18F-FDG PET/CT detected recurrent disease in most patients. Although subsequent treatment of 18F-FDG PET/CT-detected disease reduced tumour marker levels in most patients, markers remained detectable, suggesting that not all residual or metastatic disease had been identified, which compromised salvage therapy. This is the largest and most mature study to date reporting tumour marker responses to PET- or PET/CT-guided therapy in this setting.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , ,